Literature DB >> 16251833

Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness.

Mark S Sulkowski1, David L Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16251833     DOI： 10.1097/01.aids.0000192064.09281.48

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  12 in total

1.  Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy.

Authors:  Joseph Rasimas; Antonios Katsounas; Haniya Raza; Alison A Murphy; Jun Yang; Richard A Lempicki; Anu Osinusi; Henry Masur; Michael Polis; Shyam Kottilil; Donald Rosenstein
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

2.  The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.

Authors:  Tarek Hassanein; Mitchell L Shiffman; Nizar N Zein
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-06

3.  Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients.

Authors:  Antonios Katsounas; Joseph J Rasimas; Joerg F Schlaak; Richard A Lempicki; Donald L Rosenstein; Shyam Kottilil
Journal:  J Med Virol       Date:  2014-04-30       Impact factor: 2.327

4.  Mental health in HIV seronegative and seropositive IDUs in South Florida.

Authors:  Deborah L Jones; Drenna Waldrop-Valverde; Peggy Gonzalez; Alison Mack; Adarsh M Kumar; Ray Ownby; Stephen M Weiss; Mahendra Kumar
Journal:  AIDS Care       Date:  2010-02

5.  Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.

Authors:  Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta
Journal:  Int J Drug Policy       Date:  2018-04-19

6.  Health care costs associated with hepatitis C: a longitudinal cohort study.

Authors:  Mel Krajden; Margot Kuo; Brandon Zagorski; Maria Alvarez; Amanda Yu; Murray Krahn
Journal:  Can J Gastroenterol       Date:  2010-12       Impact factor: 3.522

7.  HCV co-infection in HIV positive population in British Columbia, Canada.

Authors:  Jane A Buxton; Amanda Yu; Paul H Kim; John J Spinelli; Margot Kuo; Maria Alvarez; Mark Gilbert; Mel Krajden
Journal:  BMC Public Health       Date:  2010-04-29       Impact factor: 3.295

Review 8.  A meta-analysis of the hepatitis C virus distribution in diverse racial/ethnic drug injector groups.

Authors:  Corina Lelutiu-Weinberger; Enrique R Pouget; Don D C Des Jarlais; Hannah L Cooper; Roberta Scheinmann; Rebecca Stern; Shiela M Strauss; Holly Hagan
Journal:  Soc Sci Med       Date:  2008-12-04       Impact factor: 4.634

9.  HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.

Authors:  Anu Osinusi; Joseph J Rasimas; Rachel Bishop; Michael Proschan; Mary McLaughlin; Alison Murphy; Karoll J Cortez; Michael A Polis; Henry Masur; Donald Rosenstein; Shyam Kottilil
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

10.  Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review.

Authors:  Michael G Wilson; Melisa Dickie; Curtis L Cooper; Adriana Carvalhal; Jean Bacon; Sean B Rourke
Journal:  Open Med       Date:  2009-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.